
Biofrontera Investor Relations Material
Latest events

Q1 2025
Biofrontera
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Biofrontera Inc
Access all reports
Biofrontera Inc. is a biopharmaceutical company based in the United States, engaged in the commercialization of pharmaceutical products designed to treat dermatological conditions. The company's focus is on photodynamic therapy (PDT) and topical antibiotics. Biofrontera's product portfolio includes Ameluz, a prescription drug for the treatment of actinic keratosis, a common precancerous skin condition, when used in combination with its BF-RhodoLED lamp. Another product, Xepi, is a topical cream approved for the treatment of impetigo, a bacterial skin infection. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
BFRI
Country
🇺🇸 United States